TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Company Overview - TG Therapeutics, Inc. is a fully integrated, commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [3] - BRIUMVI has also received approval from several regulatory agencies outside of the U.S. for treating adult patients with relapsing multiple sclerosis who have active disease defined by clinical or imaging features [3] Upcoming Events - Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 1:30 PM PST [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible after the event [2]